Aileen M Barnes1, Aarthi Ashok2, Elena N Makareeva3, Marina Brusel4, Wayne A Cabral5, MaryAnn Weis6, Catherine Moali7, Emmanuel Bettler7, David R Eyre6, John P Cassella8, Sergey Leikin3, David J S Hulmes7, Efrat Kessler4, Joan C Marini9. 1. Section of Heritable Disorders of Bone and Extracellular Matrix, NICHD, NIH, Bethesda, MD, United States of America. 2. Section of Heritable Disorders of Bone and Extracellular Matrix, NICHD, NIH, Bethesda, MD, United States of America; University of Toronto Scarborough, Toronto, ON, Canada. 3. Section on Physical Biochemistry, NICHD, NIH, Bethesda, MD, United States of America. 4. Goldschleger Eye Research Institute, Tel Aviv University Sackler Faculty of Medicine, Tel-Hashomer, Israel. 5. Section of Heritable Disorders of Bone and Extracellular Matrix, NICHD, NIH, Bethesda, MD, United States of America; Molecular Genetics Section, Medical Genomics and Metabolic Genetics Branch, NHGRI, NIH, Bethesda, MD, United States of America. 6. Orthopaedic Research Labs, University of Washington, Seattle, WA, United States of America. 7. Tissue Biology and Therapeutic Engineering Unit, UMR5305, CNRS/University of Lyon, Lyon, France. 8. Department of Forensic and Crime Science, Staffordshire University, Staffordshire, UK. 9. Section of Heritable Disorders of Bone and Extracellular Matrix, NICHD, NIH, Bethesda, MD, United States of America. Electronic address: oidoc@helix.nih.gov.
Abstract
Mutations in the type I procollagen C-propeptide occur in ~6.5% of Osteogenesis Imperfecta (OI) patients. They are of special interest because this region of procollagen is involved in α chain selection and folding, but is processed prior to fibril assembly and is absent in mature collagen fibrils in tissue. We investigated the consequences of seven COL1A1 C-propeptide mutations for collagen biochemistry in comparison to three probands with classical glycine substitutions in the collagen helix near the C-propeptide and a normal control. Procollagens with C-propeptide defects showed the expected delayed chain incorporation, slow folding and overmodification. Immunofluorescence microscopy indicated that procollagen with C-propeptide defects was mislocalized to the ER lumen, in contrast to the ER membrane localization of normal procollagen and procollagen with helical substitutions. Notably, pericellular processing of procollagen with C-propeptide mutations was defective, with accumulation of pC-collagen and/or reduced production of mature collagen. In vitro cleavage assays with BMP-1 ± PCPE-1 confirmed impaired C-propeptide processing of procollagens containing mutant proα1(I) chains. Overmodified collagens were incorporated into the matrix in culture. Dermal fibrils showed alterations in average diameter and diameter variability and bone fibrils were disorganized. Altered ER-localization and reduced pericellular processing of defective C-propeptides are expected to contribute to abnormal osteoblast differentiation and matrix function, respectively.
Mutations in the type I procollagenpan class="Chemical">C-propeptide occur in ~6.5% of Osteogenesis Imperfecta (OI) patients. They are of special interest because this region of procollagen is involved in α chain selection and folding, but is processed prior to fibril assembly and is absent in mature collagen fibrils in tissue. We investigated the consequences of seven COL1A1C-propeptide mutations for collagen biochemistry in comparison to three probands with classical glycine substitutions in the collagen helix near the C-propeptide and a normal control. Procollagens with C-propeptide defects showed the expected delayed chain incorporation, slow folding and overmodification. Immunofluorescence microscopy indicated that procollagen with C-propeptide defects was mislocalized to the ER lumen, in contrast to the ER membrane localization of normal procollagen and procollagen with helical substitutions. Notably, pericellular processing of procollagen with C-propeptide mutations was defective, with accumulation of pC-collagen and/or reduced production of mature collagen. In vitro cleavage assays with BMP-1 ± PCPE-1 confirmed impaired C-propeptideprocessing of procollagens containing mutant proα1(I) chains. Overmodified collagens were incorporated into the matrix in culture. Dermal fibrils showed alterations in average diameter and diameter variability and bone fibrils were disorganized. Altered ER-localization and reduced pericellular processing of defective C-propeptides are expected to contribute to abnormal osteoblast differentiation and matrix function, respectively.
Authors: Elena Makareeva; Edward L Mertz; Natalia V Kuznetsova; Mary B Sutter; Angela M DeRidder; Wayne A Cabral; Aileen M Barnes; Daniel J McBride; Joan C Marini; Sergey Leikin Journal: J Biol Chem Date: 2007-12-11 Impact factor: 5.157
Authors: William N Pappano; Barry M Steiglitz; Ian C Scott; Douglas R Keene; Daniel S Greenspan Journal: Mol Cell Biol Date: 2003-07 Impact factor: 4.272
Authors: Nadia Garibaldi; Roberta Besio; Raymond Dalgleish; Simona Villani; Aileen M Barnes; Joan C Marini; Antonella Forlino Journal: Dis Model Mech Date: 2022-05-16 Impact factor: 5.732
Authors: Ngoc-Duc Doan; Azade S Hosseini; Agata A Bikovtseva; Michelle S Huang; Andrew S DiChiara; Louis J Papa; Antonius Koller; Matthew D Shoulders Journal: J Biol Chem Date: 2020-06-01 Impact factor: 5.157
Authors: E H Campanini; D Baker; P Arundel; N J Bishop; A C Offiah; S Keigwin; S Cadden; E Dall'Ara; N Nicolaou; S Giles; J A Fernandes; M Balasubramanian Journal: Bone Rep Date: 2021-07-01